Skip to main content
. Author manuscript; available in PMC: 2010 Apr 15.
Published in final edited form as: Clin Cancer Res. 2008 Dec 10;14(24):8263–8269. doi: 10.1158/1078-0432.CCR-08-0480

Table 4.

Patient outcome according to mutually adjusted levels of plasma IGF-I and IGFBP-3

Quartile of plasma biomarker
P for trend*
1 2 3 4
Overall mortality
 IGF-I
  HR for death* (95% CI) 1.0 (reference) 0.83 (0.62-1.12) 0.59 (0.42-0.84) 0.67 (0.44-1.00) 0.12
 IGFBP-3
  HR for death* (95% CI) 1.0 (reference) 0.90 (0.68-1.20) 0.72 (0.52-0.99) 0.77 (0.52-1.13) 0.07
Tumor progression
 IGF-I
  HR for tumor progression* (95% CI) 1.0 (reference) 0.95 (0.70-1.29) 0.77 (0.54-1.09) 1.03 (0.69-1.55) 0.95
 IGFBP-3
  HR for tumor progression* (95% CI) 1.0 (reference) 0.80 (0.60-1.07) 0.66 (0.48-0.91) 0.60 (0.46-1.01) 0.03

Abbreviation: HR, hazard ratio.

*

Multivariate hazard ratios, confidence intervals, and P values adjusted for age, gender, performance status, body mass index, treatment arm, and either plasma IGF-I or IGFBP-3 levels.

HHS Vulnerability Disclosure